10 November 2022
Capimune® (ciclosporin) 25mg, 50mg and 100mg capsules shortage
The Capimune® brand of ciclosporin 25mg, 50mg and 100mg capsules are out of stock until at least mid-December 2022.
The Department of Health and Social Care (DHSC) has issued a medicine supply notification confirming that the Capimune® brand of ciclosporin 25mg, 50mg and 100mg capsules are out of stock until at least mid-December 2022.
The Deximune® brand of ciclosporin 25mg, 50mg and 100mg capsules remain available and can support an increase in demand, and alternative brands of ciclosporin capsules (Neoral®, Vanquoral®, Capsorin®, and Sandimmun®) also remain available, however these brands have limited or no availability to support an increase in demand.
It is important that people who are taking ciclosporin orally should be stabilised on a particular brand as switching between brands without close monitoring may lead to clinically important changes in ciclosporin levels in the body. Switching between brands should be carried out in consultation with a dermatologist.
If switching between brands of ciclosporin is necessary, the individual should be monitored closely for changes in ciclosporin levels (where clinically appropriate), serum creatinine, blood pressure, disease control, and adverse events.
Ciclosporin remains a popular treatment option for moderate to severe psoriasis, and so it is likely that any impact on supply will be felt particularly in areas of the treatment pathway which rely on individuals having tried methotrexate or ciclosporin before consideration of a biologic, and also in women of childbearing age where ciclosporin can be used (including, where necessary, in pregnancy).
If you are affected by this shortage of Capimune® ciclosporin capsules, we would recommend that you discuss this with your dermatology team. You can also contact our helpline for information or support.
If you have any questions or would like further information, the manufacturer, Mylan, can be contacted directly, either by phone on 01707 853 000 or email at firstname.lastname@example.org.
You can find more information about other currently unavailable treatments here.